Ernexa Stock Rockets 60% on Ovarian Cancer Trial Breakthrough

Ernexa’s stock surged 60% today after the biotech company announced promising results from its ovarian cancer trial, sending retail investors into a frenzy. The positive data has sparked widespread enthusiasm across trading communities, with traders buzzing about the potential implications for cancer treatment. The dramatic stock movement reflects investor optimism about the company’s clinical progress and the broader significance of the trial results for patients battling the disease.

AI-generated summary — triage, not the story; the byline above links out to the publisher.